Compare Capri Holdings Ltd (CPRI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs IDEXX Laboratories, Inc. — how do they compare? Capri Holdings Ltd trades at $14.84 (market cap $1.67B), while IDEXX Laboratories, Inc. trades at $519.51 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 24.2× Capri Holdings Ltd's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 3,722,279). Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CPRI | IDXX | |
|---|---|---|
Market Cap | $1.67B | $40.43B |
Volume | 3,722,279 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $766.68 |
52-Week Low | $12.71 | $504.70 |
Typical Hold Time | 41 Days | 46 Days |
Enterprise Value | $2.95B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.83, up 2.7% with bullish technical signals and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and positive analyst sentiment (44% buy ratings). However, fundamentals reveal challenges with declining revenue ($4.44B in 2025 vs $5.7B in 2022) and negative net income (-$1.18B), though profitability metrics show improvement potential with 62.7% gross margins.
The outlook balances attractive valuation (P/S 0.51) against turnaround execution risks. Upside exists if brand revitalization succeeds, but investors face headwinds from Michael Kors weakness and competitive pressures. The consensus price target of $20.57 suggests 39% potential upside if recovery gains traction in H2 2026 as management projects.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
